display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - L2 - all population
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone EAGLE ...
nivolumab based treatment
nivolumab alone CheckMate 141
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-040 ...
Immune checkpoint association
durvalumab plus tremelimumab EAGLE ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons